Paper Details

  1. Home
  2. Paper Details

Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.

Author: CaiRongman, DieussaertIlse, GaoFeng, LaunayOdile, Leroux-RoelsGeert, McPheeRoderick A, MillerJacqueline M, NguyenThi Lien-Anh, PicciolatoMarta, SchmidtAlexander C, SchwarzTino F, TalliJaak

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

An investigational respiratory syncytial virus (RSV) vaccine, RSV-PreF, was found to be well tolerated and induced RSV-A and RSV-B neutralizing antibodies in healthy, nonpregnant women. Three formulations of the vaccine, containing 30 µg, 60 µg, or 120 µg of RSV fusion protein, were tested. The 120 µg formulation elicited significantly higher antibody titers than the 30 µg formulation.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Respiratory syncytial virus (RSV) is a common cause of respiratory tract illness and hospitalization in neonates and infants. RSV vaccination during pregnancy may protect offspring in their first months of life. METHODS: This randomized, observer-blind, multicenter, phase 2 study evalua...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898794/

データ提供：米国国立医学図書館（NLM）

RSV Candidate Vaccine: A Promising Step Forward

This study focuses on the development of a candidate vaccine for respiratory syncytial virus (RSV), a common cause of respiratory illness in infants. The research evaluates the immunogenicity and safety of three different formulations of the RSV vaccine in healthy nonpregnant women. The findings demonstrate that all three formulations were well-tolerated and induced a significant increase in RSV-neutralizing antibodies, providing promising evidence for the vaccine's potential efficacy.

A Beacon of Hope in the Desert of RSV Infection

The research suggests that this RSV candidate vaccine holds significant potential for protecting infants from the debilitating effects of RSV infection. The encouraging results from this Phase 2 trial pave the way for further clinical development and evaluation, offering hope for a future where RSV infections are no longer a major health concern. It's like finding a shimmering oasis in the vast and often harsh desert of respiratory illnesses, offering a potential solution to a significant health threat.

Navigating the Desert of Vaccine Development

This research highlights the ongoing efforts to develop effective vaccines for RSV, a persistent threat to infants worldwide. The promising results from this study underscore the importance of continued research and development in the field of vaccinology. It's a journey through the desert of vaccine development, where each step forward brings us closer to a world free from the burden of RSV infections.

Dr.Camel's Conclusion

Imagine a desert where the sandstorms of RSV infection constantly threaten the health of infants. This research offers a glimmer of hope, showcasing a potential vaccine that acts like a protective dune, shielding vulnerable infants from the harsh effects of this respiratory illness. It's a promising step towards a future where RSV infections are no longer a threat to children's health.

Date :
  1. Date Completed 2020-05-19
  2. Date Revised 2020-05-19
Further Info :

Pubmed ID

31418022

DOI: Digital Object Identifier

PMC6898794

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.